#Switzerland #Zug #Berlin Heals #Dr. Eric Fain #C-MIC Therapy

Berlin Heals Welcomes Dr. Eric Fain as New Board Member

Berlin Heals Holding AG, a prominent clinical-stage medical device company, is making waves in the cardiac sector with the announcement of Dr. Eric S. Fain's appointment to its Board of Directors. This strategic decision is aimed at advancing treatment options for chronic heart failure, a condition affecting over 64 million people globally.

Dr. Fain brings more than 35 years of invaluable experience within the cardiovascular industry, aligning perfectly with Berlin Heals’ mission to revolutionize heart failure treatment. Previously, he held leadership positions at renowned organizations such as St. Jude Medical and Abbott, where he was instrumental in the research, development, and commercialization of various implantable cardiac devices. His track record in achieving successful financings and exits on both strategic and start-up sides adds a layer of expertise that is expected to be vital for Berlin Heals moving forward.

In a statement reflecting his enthusiasm, Dr. Fain shared, “Developing technology to treat heart failure is a true passion of mine, and I am honored to join Berlin Heals at such a pivotal moment in the company’s journey.” His belief in the potential of Cardiac Microcurrent (C-MIC) technology, which aims to reverse the decline of cardiac function, is particularly significant given the context of rising heart failure cases.

Berlin Heals is currently focusing on implementing a less invasive design for its C-MIC therapy, which is designed to expand the target patient population significantly. Traditionally, the therapy required a more invasive surgical procedure; however, the new plan enables a less invasive approach. As Roland Diggelmann, a board member stated, “His broad range of experience and profound expertise will render him an exceptional addition to the Berlin Heals team as we embark on our next phase of growth.”

The innovative C-MIC therapy operates through a fully implantable medical device that utilizes electrodes connected to an implantable generator, delivering a constant microcurrent to the affected heart area. This approach has proven to reduce inflammation and remodel heart structures, supporting improved cardiac function and enhanced patient quality of life. This groundbreaking therapy stands to offer heart failure patients new hope where currently there are limited treatment options.

With Dr. Fain's leadership, Berlin Heals is poised to move towards planning U.S. clinical studies and eventual submission for FDA approval. Marko Bagaric, another board member and co-founder, expressed his delight in welcoming Dr. Fain: “His extensive experience in cardiovascular device innovation will be of tremendous value as we advance C-MIC technology toward market introduction.”

Heart failure is often characterized by the heart's inability to meet the body's blood-flow demands, leading to common symptoms such as shortness of breath and fatigue. The condition is on the rise, impacting a staggering number of individuals and incurs substantial healthcare costs globally, estimated at $287 billion annually. The urgency surrounding treatment innovation is apparent given that, in developed nations, one in four individuals will face a heart failure diagnosis in their lifetime.

In light of these developments, Berlin Heals Holding AG continues to forge its path towards becoming a leader in heart failure treatment, utilizing Dr. Fain's expertise to optimize patient outcomes and expand therapeutic reach globally. His appointment to the Board signifies a promising step in the direction of innovative and accessible cardiac care solutions. As the company races toward clinical validation, patients suffering from heart failure worldwide are one step closer to potentially transformative treatments.